Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 141   

Articles published

NVS 93.56 +0.38 (0.41%)
price chart
Pharma Stock Updates - Pfizer Inc. (NYSE:PFE), Novartis AG (ADR) (NYSE:NVS ...
Novartis AG (ADR) (NYSE:NVS) said late on Wednesday that its experimental drug secukinumab worker better than a placebo in two pivotal Phase III studies on psoriatic arthritis, a long-lasting condition that causes joint pain and stiffness and which ...
Related articles »  
Novartis AG (ADR)(NYSE:NVS) Drug Signifor LAR To Be Used For Treating ...
Boston, MA 09/29/2014 (wallstreetpr) - According to reports, Novartis AG (ADR)(NYSE:NVS)'s drug Signifor LAR has got the recommendation of CHMP for the approval of EU.
Related articles »  
Traders Watch: Novartis AG (ADR) (NYSE:NVS), BlackBerry Ltd (NASDAQ ...
Novartis AG (ADR)(NYSE:NVS) noted that Signifor LAR presentation before EU is imminent following the Committee for Medicinal Products for Human Use(CHMP) recommendation.
Related articles »  
Novartis's Signifor Closer To EU Approval
Novartis AG (ADR) (NVS) announced Friday that the European Medicines Agency (EMA) committee has given positive recommendations for its drug� Signifor LAR (pasireotide)� to the European Union (EU).
Novartis Releases Positive Phase 3 Results For Psoriatic Arthritis Drug
Novartis AG (ADR) (NVS) today released top line results for two late-stage pivotal studies, which evaluated its novel drug secukinumab as a treatment for psoriatic arthritis (PsA).
Related articles »  
Sizzling news - Novartis AG (ADR) (NYSE:NVS), Royal Dutch Shell plc (NYSE ...
Manhattan, NY- September 30, 2014 - (Techsonian) - Novartis AG (ADR) (NYSE:NVS)offers patented prescription medicines in a variety of therapeutic areas, including oncology; most important care and established medicines; specialty care, such as ...
Related articles »  
Watch List Highlights - Apple Inc. (NASDAQ:AAPL), Novartis AG (ADR) (NYSE ...
Novartis AG (ADR) (NYSE:NVS) Basel disclosed Friday analyses that confirm the high efficacy of the NVS drug Gilenya (fingolimod) in achieving 'no evidence of disease activity' in patients with relapsing-remitting multiple sclerosis.
Health stocks in focus: Novartis AG (NYSE:NVS), Sanofi SA (ADR) (NYSE:SNY ...
Novartis AG (NYSE:NVS) announced Friday that the European Medicines Agency (EMA) committee has given positive recommendations for its drug� Signifor LAR (pasireotide)� to the European Union (EU).
Novartis Stock Reaches 3-Year High On Successful Heart Failure Drug Trials
Novartis AG ADR (NVS) stock rose 4.3% and closed at 85.9 Swiss francs yesterday on the Zurich Exchange. This was the stock's biggest gain since September 2011, driven by successful Phase III trials conducted on Novartis' experimental heart failure drug ...
Related articles »  
Novartis Wins The Battle Over Bronchodilators Against GSK
Novartis AG ADR (NVS) reported yesterday that its once-daily Ultibro (Breezhaler) bronchodilator outperformed GlaxoSmithKline plc's (ADR) (GSK) twice-daily blockbuster Seretide (Accuhaler) bronchodilator in Phase-III trials.
Related articles »